Mar Vista Investment Partners Has Trimmed Schlumberger LTD (SLB) Stake By $7.76 Million, Cytori Therapeutics DE (CYTX) Shorts Increased By 9.58%

July 3, 2017 - By Maria Brooks

Cytori Therapeutics DE (NASDAQ:CYTX) had an increase of 9.58% in short interest. CYTX’s SI was 1.51 million shares in July as released by FINRA. Its up 9.58% from 1.38M shares previously. With 384,500 avg volume, 4 days are for Cytori Therapeutics DE (NASDAQ:CYTX)’s short sellers to cover CYTX’s short positions. The SI to Cytori Therapeutics DE’s float is 6.84%. About 148,363 shares traded. Cytori Therapeutics Inc (NASDAQ:CYTX) has declined 65.60% since July 3, 2016 and is downtrending. It has underperformed by 82.30% the S&P500.

Mar Vista Investment Partners Llc decreased Schlumberger Ltd (SLB) stake by 7.22% reported in 2016Q4 SEC filing. Mar Vista Investment Partners Llc sold 93,483 shares as Schlumberger Ltd (SLB)’s stock declined 11.04%. The Mar Vista Investment Partners Llc holds 1.20 million shares with $100.86 million value, down from 1.29M last quarter. Schlumberger Ltd now has $93.64 billion valuation. The stock rose 1.64% or $1.08 reaching $66.92. About 1.07 million shares traded. Schlumberger Limited. (NYSE:SLB) has declined 3.30% since July 3, 2016 and is downtrending. It has underperformed by 20.00% the S&P500.

Among 5 analysts covering Cytori Therapeutics (NASDAQ:CYTX), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cytori Therapeutics had 6 analyst reports since August 8, 2015 according to SRatingsIntel. Maxim Group maintained the shares of CYTX in report on Saturday, August 8 with “Buy” rating. The firm earned “Hold” rating on Friday, September 4 by Zacks. The firm has “Buy” rating by Maxim Group given on Wednesday, May 31. TH Capital maintained the stock with “Buy” rating in Monday, August 10 report.

Cytori Therapeutics, Inc. is a biotechnology firm engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The company has market cap of $37.44 million. The Firm develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It currently has negative earnings. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation.

Mar Vista Investment Partners Llc increased Apple Inc (NASDAQ:AAPL) stake by 13,060 shares to 542,456 valued at $62.83M in 2016Q4. It also upped Nike Inc Cl B (NYSE:NKE) stake by 11,844 shares and now owns 446,404 shares. Core Laboratories N.V. (NYSE:CLB) was raised too.

Analysts await Schlumberger Limited. (NYSE:SLB) to report earnings on July, 20. They expect $0.30 earnings per share, up 30.43% or $0.07 from last year’s $0.23 per share. SLB’s profit will be $419.78 million for 55.77 P/E if the $0.30 EPS becomes a reality. After $0.25 actual earnings per share reported by Schlumberger Limited. for the previous quarter, Wall Street now forecasts 20.00% EPS growth.

Among 32 analysts covering Schlumberger Limited. (NYSE:SLB), 24 have Buy rating, 1 Sell and 7 Hold. Therefore 75% are positive. Schlumberger Limited. had 90 analyst reports since July 22, 2015 according to SRatingsIntel. Cowen & Co maintained the stock with “Outperform” rating in Monday, January 25 report. The firm has “Equal-Weight” rating given on Monday, March 28 by Barclays Capital. The firm earned “Hold” rating on Friday, May 5 by Bernstein. Atlantic Securities downgraded the shares of SLB in report on Tuesday, June 27 to “Neutral” rating. BMO Capital Markets maintained the shares of SLB in report on Friday, September 4 with “Outperform” rating. Oppenheimer maintained Schlumberger Limited. (NYSE:SLB) rating on Monday, January 25. Oppenheimer has “Outperform” rating and $92.0 target. The firm has “Buy” rating given on Wednesday, October 21 by Citigroup. The firm earned “Buy” rating on Tuesday, October 20 by Argus Research. UBS maintained the stock with “Buy” rating in Wednesday, September 30 report. FBR Capital maintained Schlumberger Limited. (NYSE:SLB) rating on Wednesday, February 22. FBR Capital has “Outperform” rating and $107 target.